Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company ...

British consumer healthcare group Haleon on Thursday said 2025 revenue and profit growth would be weighted to the second half ...

Haleon's dividend grew 10% and is well-covered by FCF, but the 1.6% yield is less attractive compared to peers. See why I ...

Hsbc Global Res lowered shares of Haleon (NYSE:HLN – Free Report) from a strong-buy rating to a hold rating in a research ...

Shares of Haleon PLC HLN slid 3.40% to £4.01 Wednesday, on what proved to be an all-around dismal trading session for the ...

The maker of Panadol, Sensodyne toothpaste and Centrum vitamins posted a higher pretax profit for 2024 despite lower revenue.

Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion.

HSBC analyst Jeremy Fialko downgraded Haleon (HLN) to Hold from Buy with a 420 GBp price target Discover the Best Stocks and Maximize Your ...

Haleon PLC HLN shares slipped 3.31% to £3.82 Thursday, on what proved to be an all-around favorable trading session for the ...

Sensodyne, a leading oral care brand from Haleon (formerly GlaxoSmithKline Consumer Healthcare), sets a GUINNESS WORLD RECORD™ for successfully attempting the 'Most online dental screening tests ...

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains ...

Haleon HLN-1.12%decrease; red down pointing triangle posted a higher pretax profit for 2024 despite lower revenue, and said it expected further organic revenue and profit growth this year.